Press releases | WebDisclosure

Basculer en Français

10940	Companies
239041	Keywords
167908	Articles
128529	Press releases

Home
Press releases

PRESS RELEASE

published on 03/18/2026 at 07:00, 5 months 20 days ago

Investis delivers strong performance – Higher dividend of CHF 3.00 proposed
Investis Holding SA reports strong financial performance with a proposed higher dividend of CHF 3.00 per share. Significant increase in rental income and property portfolio value

Financial Performance Dividend Proposal Rental Income Property Portfolio INVESTIS Holding SA
PRESS RELEASE

published on 03/18/2026 at 07:00, 5 months 20 days ago

BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025
BioVersys AG reports corporate highlights and financial results for the full year 2025, including significant progress in clinical and regulatory advancements of antibacterial products for MDR bacteria

Financial Results BioVersys AG Antibacterial Products Clinical Progress Regulatory Advancements
PRESS RELEASE

published on 03/18/2026 at 07:00, 5 months 21 days ago

Blue Cap AG publishes preliminary financial figures for 2025: successful financial year 2025
Blue Cap AG reports successful financial year 2025 with EUR 129.1 million revenue and 5.5% adjusted EBITDA margin. Focus on Industrials and Business Services segments. Forecast for 2026 remains stable

Financial Results Revenue EBITDA Margin Blue Cap AG Forecast
PRESS RELEASE

published on 03/18/2026 at 07:00, 5 months 21 days ago

Newron announces nominations to its Board of Directors at upcoming Annual General Meeting
Newron Pharmaceuticals S.p.A. announces nominations for new Board members and resignations of current members ahead of its Annual General Meeting. Full agenda to be released on March 24, 2026

Board Of Directors Annual General Meeting Nominations Newron Pharmaceuticals Resignations
REGULATED PRESS RELEASE

published on 03/18/2026 at 07:00, 5 months 21 days ago

Mersen: A resilient performance in 2025, return to growth expected in 2026
Mersen demonstrates resilient performance in 2025 with sales of €1,186 million and 2026 guidance for organic sales growth between 2% and 6%. Return to positive free cash flow ahead of schedule

Mersen Sales Growth Free Cash Flow Resilient Performance 2026 Guidance
REGULATED PRESS RELEASE

published on 03/18/2026 at 07:00, 5 months 21 days ago

Mersen : Performance résiliente en 2025, retour attendu de la croissance en 2026
Mersen affiche une performance résiliente en 2025 avec un chiffre d'affaires de 1 186 M€, une marge d'EBITDA maintenue à 16% et un retour anticipé au free cash-flow positif. Objectifs 2026 : croissance organique et marge EBITDA autour de 16%

Chiffre D'affaires Croissance EBITDA Mersen Performance
PRESS RELEASE

published on 03/18/2026 at 07:00, 5 months 21 days ago

2025 annual results: strong improvement in financial earnings and cash-flows
Exail Technologies achieved significant financial growth in 2025 with record order intake of €844 million (+87%), revenue growth of +28%, and strengthened balance sheet post fundraising of €300 million. Operational milestones include delivering mine countermeasures to navies and increasing production capacity for navigation systems

Financial Growth Record Order Intake Exail Technologies Operational Milestones Strengthened Balance Sheet
PRESS RELEASE

published on 03/18/2026 at 07:00, 5 months 21 days ago

Résultats annuels 2025 : forte amélioration des résultats et des flux de trésorerie
PRESS RELEASE

published on 03/18/2026 at 07:00, 5 months 21 days ago

Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
Sanofi's venglustat receives Breakthrough Therapy designation in the US for type 3 Gaucher disease, a rare lysosomal storage disorder. Positive results from the LEAP2MONO study show significant improvements in neurological symptoms

Sanofi Breakthrough Therapy Venglustat Gaucher Disease Neurological Symptoms
PRESS RELEASE

published on 03/18/2026 at 07:00, 5 months 21 days ago

Communiqué de presse : Le venglustat de Sanofi a reçu la désignation de thérapie innovante aux États-Unis pour la maladie de Gaucher de type 3
Sanofi's venglustat receives innovative therapy designation in the US for Gaucher disease type 3. Positive results from the LEAP2MONO study reinforce its potential as a treatment option

FDA Sanofi Innovative Therapy Venglustat Gaucher Disease

Accesswire

Published on 09/08/2026 at 01:45, 5 hours 15 minutes ago

Tunkillia Environmental Scoping Report Approved
Published on 09/05/2026 at 04:05, 3 days 2 hours ago

Pelican AI Corp. Announces Proposed Share Issuances and Litigation Update
Published on 09/04/2026 at 23:30, 3 days 7 hours ago

FutureGen Industries Announces Shares for Debt Settlement
Published on 09/04/2026 at 23:00, 3 days 8 hours ago

Golden Minerals Announces Management Change and Argentine Project Update
Published on 09/04/2026 at 22:30, 3 days 8 hours ago

Panther Minerals Closes Brokered Private Placement of $3,000,000

View all ACCESSWIRE

EQS Group

Published on 09/08/2026 at 06:30, 29 minutes ago

Ad hoc announcement pursuant to Art. 53 LR News Release
Published on 09/08/2026 at 06:20, 39 minutes ago

Guanlan AI Applications: Higher Accuracy, Lower Cost, Smarter Interaction
Published on 09/07/2026 at 19:19, 11 hours 40 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Sales and Adjusted EBIT in Q2 2026/27 above prior-year level – FY outlook maintained
Published on 09/07/2026 at 19:00, 12 hours ago

PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 31 août 2026 au 4 septembre 2026
Published on 09/07/2026 at 18:42, 12 hours 17 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 09/07/2026 at 19:55, 11 hours 4 minutes ago

TFF GROUP CREE TFF UPCYCLING
Published on 09/07/2026 at 19:00, 12 hours ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 4 septembre 2026
Published on 09/07/2026 at 19:00, 12 hours ago

Information concerning the total number of voting rights and shares in the share capital as of September 4, 2026
Published on 09/07/2026 at 18:05, 12 hours 55 minutes ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/08/2026
Published on 09/07/2026 at 18:05, 12 hours 55 minutes ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/08/2026

View all LES ECHOS COMFI WIRE